However, selective COX-2 inhibitors did not enhance the antiproliferative effect in ESCC, gastrointestinal and cardiovascular side effects for long-term use restricted their clinical application [26, 27]. The gene discussed is PTGS2; the disease is esophageal squamous cell carcinoma.